Skip to content

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)- a Cluster Randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05444348
Acronym
ACT
Enrollment
920
Registered
2022-07-05
Start date
2022-08-01
Completion date
2028-07-01
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Brief summary

Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with hematological cancers frequently have poor end of life outcomes, such as high treatment activity close to death, where clinical effects are doubtful, and low utilization of palliative care. Prognostic awareness and end of life (EOL) issues have urgency in the communication between patients, their caregiving relatives, and clinicians, in order to avoid futile treatments and suffering at EOL. Inspired by advanced care planning, the investigators developed the concept "Advance Consultations Concerning participants Life and Treatment" (ACT) in collaboration with a group consisting of hematologists, nurses, patients, and caregivers. The ACT concept consists of an 8-hour training day for clinicians, clinical tools, system changes, and preparation material for patients and caregivers prior to the consultation. ACT involves patients and caregivers earlier in preparation for life with chronic progressive disease and EOL-decisions, through an intervention based on compassionate communication and early planning of EOL-care. The aim of the study is to investigate the effect of the intervention on use of chemotherapy and quality of EOL-care in patients with hematological malignancy. Based on the results of the completed pilot study, the investigators are planning a nationwide 2-arm cluster randomized controlled trial where 40 physicians and 80 nurses across seven different hematological departments are randomized to either usual care or ACT training and completing ACT conversations. The investigators expect to include a total of 400 patients and their family caregivers. It is hypothesized that the ACT intervention will decrease use of futile chemotherapy, prepare patients and caregivers for difficult end-of-life-decisions, and improve quality of end-of-life care in hematology.

Interventions

BEHAVIORALAdvance consultation concerning your life and treatment (ACT )

The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.

Sponsors

Christoffer Johansen
Lead SponsorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Zealand University Hospital
CollaboratorOTHER
Odense University Hospital
CollaboratorOTHER
Vejle Hospital
CollaboratorOTHER
Esbjerg Hospital - University Hospital of Southern Denmark
CollaboratorOTHER
Gødstrup Hospital
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Aalborg University Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must: * Be at least 18 years of age * Have a diagnosis of one of the following: * High-risk myelodysplastic syndrome (MDS) or MDS with overlap of myeloproliferative neoplasms (high-risk MDS/MPN), * Acute myeloid leukemia(AML): Age≥80 or in palliative treatment or relapse * Lymphoma: Age≥80 or relapse or refractory or palliative treatment * Multiple myeloma(MM): Age≥80 or relapsed or refractory Have limited treatment options. Provide informed consent. Have sufficient Danish skills to complete intervention sessions and data collection An informal caregiver is identified by the patient as the primary provider of informal physical, practical or emotional support and must: * Be at least 18 years of age * Be able to accompany patients to intervention appointments * Provide informed consent * Have sufficient Danish skills to complete intervention sessions and data collection Physicians: * specialized in hematology * treating patients with High risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma * work at the same department for the entire time of intervention. Nurses: * treating patients with High-risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma * work at the same department for the entire time of intervention.

Exclusion criteria

Patient and caregiver are excluded if one of them is: \- Suffering from a severe psychiatric disorder Physicians and nurses: \- If they do not meet the inclusion criterion.

Design outcomes

Primary

MeasureTime frameDescription
Use of chemotherapy within the last 30 days of life.30 days prior to date of death, if patient dies within 18 months of follow-up period of the studyCounts of patients receiving chemotherapy in the last 30 days of their life
Change from baseline through 3,6,9,12 and 18 months follow-up in patient's anxiety symptomsbaseline, 3,6,9,12, and 18 months of follow-up. Investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Patient reported outcome of anxiety (General anxiety disorder), reporting on a 4-point scale from 0-3 with high value as worse outcome.
Change from baseline through 3,6,9,12 and 18 months follow-up in caregiver's anxiety symptomsbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Caregiver reported outcome of anxiety (General anxiety disorder), reporting on a 4-point scale from 0-3 with high value as worse outcome.

Secondary

MeasureTime frameDescription
Number of Days of hospitalized in the last 30 days of life30 days prior to date of death, if patient dies within 18 months of follow-up period of the studyCounts of days in hospital in the last 30 days of life of deceased patients
Number of medical consultations, in the last 30 days of life30 days prior to date of death,if patient dies within 18 months of follow-up period of the studyCounts of medical consultation in the last 30 days of life of deceased patients
Number of patients with referral to hospice in the last 30 days of life30 days prior to date of death, if patient dies within 18 months of follow-up period of the studyReferral to hospice and days from referral to death
Survivaldays from diagnosis to death, if patient dies within 18 months follow-up period of the studyOverall survival
Change from baseline through 3,6,9,12 and 18 months follow-up in Patient's quality of lifebaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Patient reported outcome using European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire Core 15 item palliative, 4-point scale, minimum value: 1 max value 4, higher score worse outcome
Change from baseline through 3,6,9,12 and 18 months follow-up in patients' depressive symptomsbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Patient reported outcome of depression (patient Health Questionaires), reporting on a 4-point scale from 0-3 with high value as worse outcome.
Change from baseline through 3,6,9,12 and 18 months follow-up in caregivers' depressive symptomsbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Caregiver reported outcome of depression (patient Health Questionaires), reporting on a 4-point scale from 0-3 with high value as worse outcome.
Change from baseline through 3,6,9,12 and 18 months follow-up in patient's social supportbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated meaPatient reported outcome, questionnaire: Ways of providing support, 19-item, measure on a 5-point scale ranging from "never" to "very often"
Change from baseline through 3,6,9,12 and 18 months follow-up in caregiver's social supportbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated meaCaregiver reported outcome, questionnaire: Ways of providing support, 19-item, measure on a 5-point scale ranging from "never" to "very often"
Change from baseline through 3,6,9,12 and 18 months follow-up in patient's relationship qualitybaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated meaPatient reported outcome, questionnaire: Relationship ladder, single-item, measure on a scale from 0-10, with higher value as better quality
Change from baseline through 3,6,9,12 and 18 months follow-up in caregiver's relationship qualitybaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated meaCaregiver reported outcome, questionnaire: Relationship ladder, single-item, measure on a scale from 0-10, with higher value as better quality
Change from baseline through 3,6,9,12 and 18 months follow-up in patient's satisfaction with health carebaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Patient reported outcome: Family Satisfaction With Advanced Cancer Care, measure on a 5-point scale where 1 is best and 5 is worst.
Change from baseline through 3,6,9,12 and 18 months follow-up in caregiver's satisfaction with health carebaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Caregiver reported outcome: Family Satisfaction With Advanced Cancer Care, measure on a 5-point scale where 1 is best and 5 is worst.
Change from baseline through 3,6,9,12 and 18 months follow-up in patient's prognostic understandingbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Patient reported outcome: Prognostic understanding, single item questionnaire
Change from baseline through 3,6,9,12 and 18 months follow-up in caregiver Prognostic understandingbaseline, 3,6,9,12, and 18 months of follow-up. investigator will use mixed effects models to utilize the repeated measurements at 3, 6, 9, 12, and 18, months follow-up.Caregiver reported outcome: Prognostic understanding, single item questionnaire
Patient satisfaction with intervention sessions7 days after each ACT intervention session through the study until 8 months of follow-up for intervention groupPatient reported outcome: Satisfaction with intervention sessions, questionnaire developed for the intervention, 5 point scale from 1-5, higher score is better outcome.
Caregiver Satisfaction with intervention sessions7 days after each ACT intervention session through the study until 8 months of follow-up for intervention groupCaregiver reported outcome: Satisfaction with intervention sessions, questionnaire developed for the intervention, 5 point scale from 1-5, higher score is better outcome.
Bereaved caregivers' depressive symptoms1 and 6 months after patient's death, if the patient dies within 18 months follow-up period of the study.Caregiver reported outcome of depression (patient Health Questionaires), reporting on a 4-point scale from 0-3 with high value as worse outcome.
Bereaved caregivers' anxiety symptoms1 and 6 months after patient's death, if the patient dies within 18 months follow-up period of the studyCaregiver reported outcome of anxiety (General anxiety disorder), reporting on a 4-point scale from 0-3 with high value as worse outcome.
Post-traumatic stress1 and 6 months after patient's death, if patient dies within 18 months of follow-up period of the studyBereaved caregiver reported outcome: post-traumatic stress using questionnaire "Impact of Events Scale- revised", assesses subjective distress caused by traumatic events, Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). Higher score worse outcome
Perception of the patient's quality of deathOne months after patient's death, if patient dies within 18 months of follow-up period of the studyBereaved caregiver reported outcome: Perception of the patient's quality of death, The Views Of Informal Carers - Evaluation of Services - Short Form.
Prolonged Griefsix months after patient's death, if patient dies within 18 months of follow-up period of the studyBereaved caregiver reported outcome: Prolonged Grief disorder. using a 5-point scale from 1-5, Higher score means worse outcome
Self-efficacy - advance care planningBaseline, and after completion of 5 ACT-intervention sessions (intervention group) through study completion, an average of 1 year, and after 24 months of intervention.Clinician reported outcome: Advance care planning self-efficacy, 5 point scale from 1-5, higher score is better outcome
BurnoutBaseline, and after completion of 5 ACT-intervention sessions (intervention group) through study completion, an average of 1 year, and after 24 months of intervention.Clinician reported outcome: burnout (Copenhagen Burnout Inventory) 5-point scale, value 0-5, higher score means worse outcome
Existential communicationBaseline, and after completion of 5 ACT-intervention sessions (intervention group) through study completion, an average of 1 year, and after 24 months of intervention.Clinician reported outcome: Existential communication, 5 point scale from 1-5, higher score is better outcome.
Satisfaction with interventionAfter completion of 5 ACT-intervention sessions (intervention group) through study completion, an average of 1 year,Clinician reported outcome: satisfaction with intervention, questionnaire developed for the intervention, 5 point scale from 1-5, higher score is better outcome.

Countries

Denmark

Contacts

CONTACTCæcilie Borregaard Myrhøj, MScN
caecilie.borregaard.myrhoej@regionh.dk+45 60701620
CONTACTAnnika von Heymann, PhD
annika.von.heymann@regionh.dk+45 21310881
PRINCIPAL_INVESTIGATORChristoffer Johansen, Professor

Rigshospitalet, Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026